Eltrombopag olamine and Deep venous thrombosis - a phase IV clinical study of FDA data

Summary:

Deep venous thrombosis is reported as a side effect among people who take Eltrombopag olamine (eltrombopag olamine), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Dexamethasone, and have Glomerulonephritis rapidly progressive.

The phase IV clinical study analyzes which people have Deep venous thrombosis when taking Eltrombopag olamine. It is created by eHealthMe based on reports of 3,901 people who have side effects when taking Eltrombopag olamine from the FDA, and is updated regularly.

What is Eltrombopag olamine?

Eltrombopag olamine has active ingredients of eltrombopag olamine. eHealthMe is studying from 3,901 Eltrombopag olamine users. Check the latest studies of Eltrombopag olamine.

What is Deep venous thrombosis?

Deep venous thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis) is found to be associated with 2,070 drugs and 2,964 conditions by eHealthMe. Check the latest studies of Deep venous thrombosis.

On Jul, 15, 2026

3,901 people reported to have side effects when taking Eltrombopag olamine.
Among them, 32 people (0.82%) have Deep venous thrombosis.

Could Eltrombopag olamine cause Deep venous thrombosis?

Among these 32 people:

How long have people been on Eltrombopag olamine when they have Deep venous thrombosis? *

What is the gender of people who have Deep venous thrombosis when taking Eltrombopag olamine? *

female: 43.48 %
male: 56.52 %

What is the age of people who have Deep venous thrombosis when taking Eltrombopag olamine? *

What are other drugs people take besides Eltrombopag olamine? *

What are other side effects people have besides Deep venous thrombosis? *

Thrombocytopenia (decrease of platelets in blood): 14 people, 43.75%
Platelet Count Increased: 8 people, 25.00%
Pulmonary Embolism (blockage of the main artery of the lung): 8 people, 25.00%
Fibula Fracture: 6 people, 18.75%
Thrombosis (formation of a blood clot inside a blood vessel): 6 people, 18.75%
Fatigue (feeling of tiredness): 6 people, 18.75%
Drug Ineffective: 5 people, 15.62%
Hypoxic-Ischaemic Encephalopathy (a condition that occurs when the entire brain is deprived of an adequate oxygen supply, but the deprivation isn't total): 4 people, 12.50%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 4 people, 12.50%
Cardio-Respiratory Arrest (sudden dysfunction of heart and lungs): 4 people, 12.50%

What are the existing conditions these people have? *

Glomerulonephritis Rapidly Progressive (a syndrome of the kidney that is characterized by a rapid loss of renal function): 4 people, 12.50%
Aplastic Anemia: 2 people, 6.25%
Transplant Rejection (a transplant material is not worked): 1 person, 3.12%
Glomerulonephritis (a group of conditions that affect parts of the kidneys called glomeruli): 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Eltrombopag olamine and have Deep venous thrombosis?

- Check whether Deep venous thrombosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eltrombopag olamine:

Eltrombopag olamine (3,901 reports)

Browse all side effects of Eltrombopag olamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Deep venous thrombosis:

Deep venous thrombosis (2,070 drugs)

Browse all the conditions that are associated with Deep venous thrombosis:

Deep venous thrombosis (2,964 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eltrombopag olamine (the active ingredients of Eltrombopag olamine) and Eltrombopag olamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.